BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-101556143 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-101556143\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06095089-11219@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:JNJ-101556143: Phase 1 readout est. (NCT06095089)
DESCRIPTION:JNJ-101556143\, phase 1\, Prostate Cancer.\nStudy: A Study of J
 NJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer\nEstim
 ated primary completion: 21 June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/jnj-101556143#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06095089
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05818683-11219@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:JNJ-101556143: Phase 1 readout est. (NCT05818683)
DESCRIPTION:JNJ-101556143\, phase 1\, Prostate Cancer.\nStudy: A Study of P
 asritamig (JNJ-78278343) in Combination With Other Agents for Metastatic P
 rostate Cancer\nEstimated primary completion: 31 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/jnj-101556143#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05818683
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906717-11219@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:JNJ-101556143: Phase 3 readout est. (NCT07906717)
DESCRIPTION:JNJ-101556143\, phase 3\, Prostate Cancer.\nStudy: A Study of J
 NJ-101556143 With Best Supportive Care in Participants With Metastatic Pro
 state Cancer\nEstimated primary completion: 14 February 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/jnj-101556143#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07906717
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06800313-11219@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:JNJ-101556143: Phase 1/2 readout est. (NCT06800313)
DESCRIPTION:JNJ-101556143\, phase 1/2\, Prostate Cancer.\nStudy: Study of H
 LD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer\nEstim
 ated primary completion: 17 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/jnj-101556143#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06800313
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832292-11219@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20290517
DTEND;VALUE=DATE:20290518
SUMMARY:JNJ-101556143: Phase 2 readout est. (NCT07832292)
DESCRIPTION:JNJ-101556143\, phase 2\, Prostate Cancer.\nStudy: A Study of J
 NJ-101556143 in Participants With Metastatic Prostate Cancer\nEstimated pr
 imary completion: 17 May 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/jnj-101556143#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07832292
URL:https://assetmemo.bio/drug/jnj-101556143#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
